[
  {
    "ts": null,
    "headline": "A Look At Viatris (VTRS) Valuation After Recent Regulatory And Pipeline Milestones",
    "summary": "Viatris (VTRS) shares are back in focus after the company reported four regulatory milestones, including US FDA approval for a generic octreotide acetate injectable and progress on contraceptive, gene therapy, and sleep-disorder treatments. See our latest analysis for Viatris. These pipeline updates arrive as Viatris shares trade at $12.46, with a 30 day share price return of 14.0% and a 90 day share price return of 22.88%, while the 1 year total shareholder return is 9.57% and the 3 year...",
    "url": "https://finnhub.io/api/news?id=00ee4fa0273c630df1c7fb4cac2aac21cfb24f235e2b601a9359ffdf3b84af67",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767625704,
      "headline": "A Look At Viatris (VTRS) Valuation After Recent Regulatory And Pipeline Milestones",
      "id": 137991682,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VTRS",
      "source": "Yahoo",
      "summary": "Viatris (VTRS) shares are back in focus after the company reported four regulatory milestones, including US FDA approval for a generic octreotide acetate injectable and progress on contraceptive, gene therapy, and sleep-disorder treatments. See our latest analysis for Viatris. These pipeline updates arrive as Viatris shares trade at $12.46, with a 30 day share price return of 14.0% and a 90 day share price return of 22.88%, while the 1 year total shareholder return is 9.57% and the 3 year...",
      "url": "https://finnhub.io/api/news?id=00ee4fa0273c630df1c7fb4cac2aac21cfb24f235e2b601a9359ffdf3b84af67"
    }
  }
]